Oxford Cannabinoid Technologies Holdings plc
Company Profile
Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs.
To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Our primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.
Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.
Investor Access
The Company will host a live presentation and Q&A via the Investor Meet Company platform at 16.00 BST on Wednesday 19 July 2023.
Recently appointed Chief Medical Officer, Dr Tim Corn and Chief Scientific Officer, Dr Valentino Parravicini, will discuss developments across the Company’s portfolio.
(https://www.londonstockexchange.com/news-article/OCTP/investor-presentation-and-q-a-programmes-update/16037031)| Event | Date |
| Year End | 30 April |
| Half Year End | 31 October |
| Preliminary Results* | July |
| Interim Results* | January |
| AGM* | November |
* Months based on previous announcements of this kind
